Indus Capital Partners’s NextCure NXTC Stock Holding History

Indus Capital Partners’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-7,892	Closed	-$3.51M	–	50
2020 Q1	$3.51M	Buy	7,892 +4,730	+150%	+$2.53M	0.59%	32
2019 Q4	$2.14M	Sell	3,162 -1,371	-30%	-$688K	0.42%	33
2019 Q3	$1.68M	Sell	4,533 -3,296	-42%	-$1.07M	0.28%	35
2019 Q2	$1.41M	Buy	+7,829	New	+$1.63M	0.23%	31

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

CPX

Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Indus Capital Partners's NXTC Position: Q2 2020 in Review

Indus Capital Partners sold out of NextCure (NXTC) in Q2 2020, closing a stake of 7,892 shares — an estimated $3.51M sold.

Indus Capital Partners first reported a position in NXTC in Q2 2019 and held it in 4 quarters. The position peaked at $3.51M in Q1 2020. 88 funds tracked by Wall St. Rank hold NXTC as of Q2 2020.

Indus Capital Partners reported no remaining NextCure position as of Q2 2020 after selling out during the quarter.
Indus Capital Partners sold 7,892 NextCure shares in Q2 2020, an estimated $3.51M.
Indus Capital Partners first reported a position in NextCure in Q2 2019 and held it in 4 quarters.
Indus Capital Partners's NextCure position peaked at $3.51M in Q1 2020.
88 funds tracked by Wall St. Rank held NextCure as of Q2 2020.

Based on Indus Capital Partners's 13F filing for Q2 2020, filed 13 Aug 2020.